Search Result

Results for "

weak base

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adrenergic Receptor (1) Akt (1) Bacterial (3) Biochemical Assay Reagents (1) c-Kit (1) Calcium Channel (1) Casein Kinase (1) Caspase (1) CDK (1) DNA/RNA Synthesis (1) Drug Derivative (1) Endogenous Metabolite (2) ERK (1) FGFR (1) FLT3 (1) Fluorescent Dye (1) IRAK (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (2) nAChR (1) Opioid Receptor (1) Parasite (2) PDGFR (1) Renin (1) RET (1) Ribosomal S6 Kinase (RSK) (1) SGK (1) STAT (1) VEGFR (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (6)

By Targets:

5-HT Receptor (3)

Adrenergic Receptor (1)

Akt (1)

Bacterial (3)

Biochemical Assay Reagents (1)

c-Kit (1)

Calcium Channel (1)

Casein Kinase (1)

Caspase (1)

CDK (1)

DNA/RNA Synthesis (1)

Drug Derivative (1)

Endogenous Metabolite (2)

ERK (1)

FGFR (1)

FLT3 (1)

Fluorescent Dye (1)

IRAK (1)

Isotope-Labeled Compounds (1)

Mitochondrial Metabolism (2)

nAChR (1)

Opioid Receptor (1)

Parasite (2)

PDGFR (1)

Renin (1)

RET (1)

Ribosomal S6 Kinase (RSK) (1)

SGK (1)

STAT (1)

VEGFR (2)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (1)

Metabolic Disease (1)

Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-133028

CKI-7 free base 1 Publications Verification	Casein Kinase CDK SGK Ribosomal S6 Kinase (RSK)	Cancer
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC₅₀ of 6 μM and a K_i of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases .

HY-D1191

SYBR green I chloride 3 Publications Verification	Fluorescent Dye DNA/RNA Synthesis	Others
SYBR Green I chloride is a highly sensitive fluorescent nucleic acid dye that binds specifically to the minor groove of double-stranded DNA or intercalates between base pairs. SYBR Green I chloride exhibits weak fluorescence in the unbound state but emits bright fluorescence upon binding, and it preferentially binds to large-fragment DNA and DNA with high G+C content. SYBR Green I chloride is suitable for real-time PCR technology; its fluorescence intensity correlates with the amount and size of amplification products, enabling accurate quantification of gene expression and discrimination of amplicons via melting curve analysis without additional post-processing. SYBR Green I chloride is widely used in preclinical in vitro nucleic acid detection .

HY-B0383A

Almotriptan PNU180638 free base	5-HT Receptor	Neurological Disease
Almotriptan (PNU180638 free base) is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan can be used in research related to migraine .

HY-171992

COX-2-IN-55	VEGFR Caspase Calcium Channel	Cancer
COX-2-IN-55 (compound 1) is an orally active, Celecoxib (HY-14398)-based analog with broad-spectrum anticancer activity and weak COX-2 inhibition. COX-2-IN-55 specifically inhibits SERCA2, increases caspase-3 cleavage and DR5 levels, thereby activating GRP78 and inhibiting the development of triple-negative breast cancer (TNBC). COX-2-IN-55 can also downregulate the levels of angiogenic markers VEGF-α and IL-8, inhibiting the formation of microvessels .

HY-W095635

Tetramethylammonium fluoride tetrahydrate	Biochemical Assay Reagents	Others
Tetramethylammonium fluoride tetrahydrate (TMAF) is a quaternary ammonium salt. TMAF is commonly used as a weak base and a source of fluoride ions in various organic reactions, including nucleophilic substitution, functional group deprotection, and ring-opening polymerization. Unlike other fluoride sources, TMAF is compatible with many functional groups, making it a versatile tool in synthetic chemistry. Functional reagents, In addition, TMAF has been used as a fluorinating agent in medicinal chemistry, for the preparation of radiotracers and protein modification in biochemistry, and the tetrahydrate form of TMAF is more stable and easier to handle than the anhydrous form.

HY-12720

Apraclonidine ALO 2145 free base	Adrenergic Receptor	Infection Neurological Disease
Apraclonidine (ALO 2145 (free base)), a selective α2 and weak α1 receptor agonist activity, effectively low intraocular pressure (IOP) in human eyes. Apraclonidine hydrochloride is a topical ophthalmic solution .

HY-19688B

Sitamaquine tosylate WR 6026 tosylate	Parasite Mitochondrial Metabolism	Infection
Sitamaquine (WR6026) tosylate, an orally active 8-aminoquinoline analog, is an antileishmanial agent. Sitamaquine tosylate inhibits mitochondrial complex II (succinate dehydrogenase). Sitamaquine tosylate is a lipophilic weak base that rapidly accumulates in acidic compartments of Leishmania spp., mainly in acidocalcisomes .

HY-12959

Repinotan BAY x 3702 free base	5-HT Receptor	Neurological Disease
Repinotan (BAY x 3702 free base) is a potent, selective, brain-penetrant and orally active 5-HT1A receptor agonist, with K_i values of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex), and 0.59 nM (rat hippocampus). Repinotan has a weak affinity for other related receptors. Repinotan has pronounced neuroprotective effects .

HY-171807

TC-2559 free base	nAChR STAT	Neurological Disease Inflammation/Immunology
TC-2559 free base is a α4β2 nicotinic acetylcholine receptor (nAChR) agonists with an EC₅₀ of 0.18 μM. TC-2559 free base shows much weaker potencies on the group of b4-containing nAChR subtypes, α2β4, α4β4 and α3β4 receptors, with EC₅₀s in the range of 10-30 µM. TC-2559 free base can increase the discharge of dopamine cells in the ventral tegmental area (VTA) of rats in vitro, enhancing the excitability and aggressive behavior of VTA dopamine neurons. TC-2559 free base inhibits STAT3 to exert anti-inflammatory properties and relieves mice mechanical allodynia and improve rats cognitive deficits. TC-2559 free base can be used for the study of nerve pain .

HY-N14344

Manumycin G	Bacterial	Infection
Manumycin G has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin G inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-19688A

Sitamaquine hydrochloride WR 6026 hydrochloride	Parasite Mitochondrial Metabolism	Infection
Sitamaquine (WR6026) hydrochloride, an orally active 8-aminoquinoline analog, is an antileishmanial agent. Sitamaquine hydrochloride inhibits mitochondrial complex II (succinate dehydrogenase). Sitamaquine hydrochloride is a lipophilic weak base that rapidly accumulates in acidic compartments of Leishmania spp., mainly in acidocalcisomes .

HY-P2753

Sucrose phosphorylase 1 Publications Verification SP	Endogenous Metabolite	Others Cancer
Sucrose phosphorylase is a bacterial transglucosidase that catalyzes the conversion of sucrose and phosphate into α-D-glucose-1-phosphate and D-fructose. The glucosylated Sucrose phosphorylase can also be hydrolyzed into α-D-glucose, or transfer the glucoyl to the hydroxyl group of the receptor, and then decomposed into new α-D-glucoside products. The enzymatic activity of base phosphorylase to substrate and product is weak .

HY-19145

PD-134672 CI-992	Renin	Cancer
PD-134672 (CI-992) is a renin inhibitor containing a 2-amino-4-thiazolyl substituent. PD-134672 potently inhibits monkey renin in vitro and only weakly inhibits the related aspartic protease bovine feline hepsin D. The compound exhibits oral hypotensive activity in hyperreninemic normotensive monkeys. Based on its superior efficacy and long-lasting effects in vitro and in the normotensive macaque model, PD-134672 was selected for further evaluation in renal hypertensive monkeys.

HY-B0383AS2

Almotriptan-d3 benzoate PNU180638 free base-d₃ benzoate	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Almotriptan-d₃ benzoate (PNU180638 free base-d₃) is deuterated labeled Almotriptan benzoate. Almotriptan benzoate is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan benzoate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan benzoate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan benzoate can be used in research related to migraine.

HY-N14342

Manumycin E	Bacterial	Infection
Manumycin E has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin E inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-N14343

Manumycin F	Bacterial	Infection
Manumycin F has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin F inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-111259

Ro 31-1118 free base	Endogenous Metabolite	Cardiovascular Disease
Ro 31-1118 Free base is a compound exhibiting weak antihypertensive activity in patients with mild hypertension. Ro 31-1118 Free base demonstrated a reduction in heart rates and blood pressure post-exercise at varying doses. Ro 31-1118 Free base exhibited linear pharmacokinetics within the 10-80 mg dose range. Ro 31-1118 Free base showed no significant impact on diastolic blood pressure or adverse effects during the study.

HY-105525

Sameridine NIH 10908 free base	Opioid Receptor	Neurological Disease
Sameridine (NIH-10908 free base) is a weak partial agonist of the μ-opioid receptor. Sameridine shows local anesthetic and analgesic properties. Sameridine has minimal respiratory depression at low doses, but can suppress ventilatory response at high doses. Sameridine can be used for the study of analgesic effect .

HY-N15947

Trifunctional sphingosine	Drug Derivative	Metabolic Disease
Trifunctional sphingosine is a clickable sphingoid base derivative. Trifunctional sphingosine can be used to study the biological function of sphingoid bases. Trifunctional lipids may overcome several challenges in interrogating lipid biology: their fast metabolism, their weak and transient (but functionally important) interactions with proteins, and the difficulty in tagging them without disturbing the cellular location .

HY-W075283

4-(1,2,2-Triphenylvinyl)aniline 1-(4-Aminophenyl)-1,2,2-triphenylethene		Others
4-(1,2,2-Triphenylvinyl)aniline (1-(4-Aminophenyl)-1,2,2-triphenylethene) is a tetraphenylethene-based aggregation-induced luminescent molecule. 4-(1,2,2-Triphenylvinyl)aniline exhibits weak or no fluorescence in dilute solution/dispersed state, and strong fluorescence with increased quantum yield when aggregated into nanoparticles .

HY-182354

VEGFR2-IN-84	VEGFR FGFR FLT3 PDGFR RET Akt ERK c-Kit	Cancer
VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. VEGFR2-IN-84 inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 blocks the phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathway, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis. VEGFR2-IN-84 exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and renal cancer, shows weak toxicity to normal cells, and has superior potency to Lenvatinib (HY-10981). VEGFR2-IN-84 possesses favorable pharmacokinetic properties and high safety (LD₅₀>2000 mg/kg), and can be used in related studies of various malignant tumors .

Cat. No.	Product Name

HY-L942

Allosteric Modulator Fragment Library	1802 compounds
In contrast to the high conservation of conventional orthosteric sites, allosteric sites possess structural characteristics of low conservation, high hydrophobicity, weak polarity, confined spatial geometry, and dynamic cryptic properties. There is a significant difference between their core structures and orthosteric pockets — allosteric pockets are mostly dynamic grooves formed by protein conformational changes, subunit interface clefts, or shallow depressions, rather than the rigid "keyhole" structure of orthosteric sites. With looser spatial constraints, allosteric sites have the advantages of high selectivity and low off-target risk, and have become an important direction in new drug discovery. Based on the dynamic, hydrophobic, and narrow-long spatial characteristics of allosteric pockets, MCE has performed targeted modification and screening of fragments. The screening criteria strictly conform to the requirements of allosteric binding: molecular weight is controlled at 120–280 Da (to meet the core needs of small molecules in fragment libraries and high derivatization), hydrogen bond donors (HBD ≤ 2), hydrogen bond acceptors (HBA ≤ 3), polar surface area (PSA = 30–80 Å²), rotatable bonds (≤ 2), moderate hydrophobicity (cLogP = 1–3.5), no strongly ionizable groups, and both appropriate rigidity and conformational flexibility to adapt to the dynamic changes of the pocket. Meanwhile, combined with the results of principal moment of inertia (PMI) analysis, fragments with high 3D diversity were obtained. Such fragments have good shape complementarity with allosteric pockets, ensuring that the fragments can smoothly enter the allosteric pockets and form stable binding, while providing room for subsequent optimization and derivation. This library contains 1,800 structurally diverse fragment molecules with excellent drug-like properties, suitable for allosteric drug development and the design and optimization of allosteric sites. It combines the

Allosteric Modulator Fragment Library

1802 compounds

In contrast to the high conservation of conventional orthosteric sites, allosteric sites possess structural characteristics of low conservation, high hydrophobicity, weak polarity, confined spatial geometry, and dynamic cryptic properties. There is a significant difference between their core structures and orthosteric pockets — allosteric pockets are mostly dynamic grooves formed by protein conformational changes, subunit interface clefts, or shallow depressions, rather than the rigid "keyhole" structure of orthosteric sites. With looser spatial constraints, allosteric sites have the advantages of high selectivity and low off-target risk, and have become an important direction in new drug discovery.

Based on the dynamic, hydrophobic, and narrow-long spatial characteristics of allosteric pockets, MCE has performed targeted modification and screening of fragments. The screening criteria strictly conform to the requirements of allosteric binding: molecular weight is controlled at 120–280 Da (to meet the core needs of small molecules in fragment libraries and high derivatization), hydrogen bond donors (HBD ≤ 2), hydrogen bond acceptors (HBA ≤ 3), polar surface area (PSA = 30–80 Å²), rotatable bonds (≤ 2), moderate hydrophobicity (cLogP = 1–3.5), no strongly ionizable groups, and both appropriate rigidity and conformational flexibility to adapt to the dynamic changes of the pocket. Meanwhile, combined with the results of principal moment of inertia (PMI) analysis, fragments with high 3D diversity were obtained. Such fragments have good shape complementarity with allosteric pockets, ensuring that the fragments can smoothly enter the allosteric pockets and form stable binding, while providing room for subsequent optimization and derivation.

This library contains 1,800 structurally diverse fragment molecules with excellent drug-like properties, suitable for allosteric drug development and the design and optimization of allosteric sites. It combines the

HY-L941

Allosteric Modulator Lead‑like Compound Library	4315 compounds
Owing to the high conservation of orthosteric sites, conventional orthosteric drugs frequently suffer from poor subtype selectivity, off-target toxicity, and drug resistance, severely restricting their clinical application. In contrast, allosteric sites feature low conservation, high hydrophobicity, weak polarity, confined spatial geometry, and dynamic cryptic properties. These characteristics endow allosteric modulators with distinct advantages including high selectivity, functional tunability, and improved safety, making allosteric therapy a key direction in modern drug discovery. MCE has curated nearly 1,000 structurally disclosed clinical-stage allosteric modulators. By analyzing allosteric protein–ligand complex structures from the PDB database, we extracted core pharmacophores and privileged scaffolds. Adopting a rational design strategy of “scaffold derivation + allosteric physicochemical filtering”, we performed secondary screening on the derived compounds strictly following the optimal physicochemical principles for allosteric binding based on universal allosteric pocket properties: molecular weight 300–500 Da, HBD ≤ 3, HBA = 3–8, PSA = 70–120 Å², rotatable bonds ≤ 6, highly rigid scaffolds, cLogP = 1.0–3.8, and no strongly ionizable groups. The selected compounds exhibit high rigidity and shape complementarity, making them well-suited for targeting shallow, dynamic, and hydrophobic-dominated allosteric pockets. This allosteric modulator library contains 4,315 structurally diverse, lead-like compounds dedicated to allosteric drug development, allosteric site targeting, and allosteric modulator screening. It is suitable for kinases, GPCRs, and other important drug targets. All compounds are analogs of clinical-stage allosteric modulators with a similarity score > 0.6, combining excellent druggability and allosteric binding potential. It provides a highly efficient tool for early-stage allosteric drug discovery.

Allosteric Modulator Lead‑like Compound Library

4315 compounds

Owing to the high conservation of orthosteric sites, conventional orthosteric drugs frequently suffer from poor subtype selectivity, off-target toxicity, and drug resistance, severely restricting their clinical application. In contrast, allosteric sites feature low conservation, high hydrophobicity, weak polarity, confined spatial geometry, and dynamic cryptic properties. These characteristics endow allosteric modulators with distinct advantages including high selectivity, functional tunability, and improved safety, making allosteric therapy a key direction in modern drug discovery.

MCE has curated nearly 1,000 structurally disclosed clinical-stage allosteric modulators. By analyzing allosteric protein–ligand complex structures from the PDB database, we extracted core pharmacophores and privileged scaffolds. Adopting a rational design strategy of “scaffold derivation + allosteric physicochemical filtering”, we performed secondary screening on the derived compounds strictly following the optimal physicochemical principles for allosteric binding based on universal allosteric pocket properties: molecular weight 300–500 Da, HBD ≤ 3, HBA = 3–8, PSA = 70–120 Å², rotatable bonds ≤ 6, highly rigid scaffolds, cLogP = 1.0–3.8, and no strongly ionizable groups. The selected compounds exhibit high rigidity and shape complementarity, making them well-suited for targeting shallow, dynamic, and hydrophobic-dominated allosteric pockets.

This allosteric modulator library contains 4,315 structurally diverse, lead-like compounds dedicated to allosteric drug development, allosteric site targeting, and allosteric modulator screening. It is suitable for kinases, GPCRs, and other important drug targets. All compounds are analogs of clinical-stage allosteric modulators with a similarity score > 0.6, combining excellent druggability and allosteric binding potential. It provides a highly efficient tool for early-stage allosteric drug discovery.

Cat. No.	Product Name	Type

HY-D1191

SYBR green I chloride 3 Publications Verification	Fluorescent Dyes
SYBR Green I chloride is a highly sensitive fluorescent nucleic acid dye that binds specifically to the minor groove of double-stranded DNA or intercalates between base pairs. SYBR Green I chloride exhibits weak fluorescence in the unbound state but emits bright fluorescence upon binding, and it preferentially binds to large-fragment DNA and DNA with high G+C content. SYBR Green I chloride is suitable for real-time PCR technology; its fluorescence intensity correlates with the amount and size of amplification products, enabling accurate quantification of gene expression and discrimination of amplicons via melting curve analysis without additional post-processing. SYBR Green I chloride is widely used in preclinical in vitro nucleic acid detection .

SYBR green I chloride

3 Publications Verification

Fluorescent Dyes

SYBR Green I chloride is a highly sensitive fluorescent nucleic acid dye that binds specifically to the minor groove of double-stranded DNA or intercalates between base pairs. SYBR Green I chloride exhibits weak fluorescence in the unbound state but emits bright fluorescence upon binding, and it preferentially binds to large-fragment DNA and DNA with high G+C content. SYBR Green I chloride is suitable for real-time PCR technology; its fluorescence intensity correlates with the amount and size of amplification products, enabling accurate quantification of gene expression and discrimination of amplicons via melting curve analysis without additional post-processing. SYBR Green I chloride is widely used in preclinical in vitro nucleic acid detection .

Cat. No.	Product Name	Type

HY-W095635

Tetramethylammonium fluoride tetrahydrate	Biochemical Assay Reagents
Tetramethylammonium fluoride tetrahydrate (TMAF) is a quaternary ammonium salt. TMAF is commonly used as a weak base and a source of fluoride ions in various organic reactions, including nucleophilic substitution, functional group deprotection, and ring-opening polymerization. Unlike other fluoride sources, TMAF is compatible with many functional groups, making it a versatile tool in synthetic chemistry. Functional reagents, In addition, TMAF has been used as a fluorinating agent in medicinal chemistry, for the preparation of radiotracers and protein modification in biochemistry, and the tetrahydrate form of TMAF is more stable and easier to handle than the anhydrous form.

Tetramethylammonium fluoride tetrahydrate

Biochemical Assay Reagents

Tetramethylammonium fluoride tetrahydrate (TMAF) is a quaternary ammonium salt. TMAF is commonly used as a weak base and a source of fluoride ions in various organic reactions, including nucleophilic substitution, functional group deprotection, and ring-opening polymerization. Unlike other fluoride sources, TMAF is compatible with many functional groups, making it a versatile tool in synthetic chemistry. Functional reagents, In addition, TMAF has been used as a fluorinating agent in medicinal chemistry, for the preparation of radiotracers and protein modification in biochemistry, and the tetrahydrate form of TMAF is more stable and easier to handle than the anhydrous form.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N14344

Manumycin G	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial
Manumycin G has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin G inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-N14342

Manumycin E	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial
Manumycin E has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin E inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-N14343

Manumycin F	Microorganisms Antibiotics Other Antibiotics Source Classification	Bacterial
Manumycin F has anti-Gram-positive bacteria and Escherichia coli effects, but the effect is very weak against other anti-Gram-negative bacteria, and has no effect on fungi. Manumycin F inhibits RAS Faraday base transfer and has weak cytotoxic activity against human cloned cancer cell lines HCT-116 (IC₅₀ is 15.6 μg/mL) .

HY-N15947

Trifunctional sphingosine	Lipid	Drug Derivative
Trifunctional sphingosine is a clickable sphingoid base derivative. Trifunctional sphingosine can be used to study the biological function of sphingoid bases. Trifunctional lipids may overcome several challenges in interrogating lipid biology: their fast metabolism, their weak and transient (but functionally important) interactions with proteins, and the difficulty in tagging them without disturbing the cellular location .

Cat. No.	Product Name	Chemical Structure

HY-B0383AS2

Almotriptan-d3 benzoate
Almotriptan-d₃ benzoate (PNU180638 free base-d₃) is deuterated labeled Almotriptan benzoate. Almotriptan benzoate is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan benzoate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan benzoate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan benzoate can be used in research related to migraine.

Almotriptan-d3 benzoate

Almotriptan-d₃ benzoate (PNU180638 free base-d₃) is deuterated labeled Almotriptan benzoate. Almotriptan benzoate is an orally active, highly selective agonist of the 5-HT_1B/1D receptor (5-HT_1B/1D receptor), with EC₅₀ values of 1.6 nM and 3.1 nM, respectively. Almotriptan benzoate shows moderate affinity for the 5-HT1F receptor, and weak affinity for the 5-HT1A, 5-HT6 and 5-HT7 receptors. Almotriptan benzoate induces intracranial vasoconstriction, inhibits nociceptive neurotransmission in the trigeminocervical complex, and suppresses the release of vasoactive peptides from trigeminal nerve endings. Almotriptan benzoate can be used in research related to migraine.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

weak base

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Natural
Products